A new treatment for pancreatic cancer using targeted drug delivery
Official title: An Aptamer-directed IgG1-Fc Drug Conjugate (AFDC) for Treating Pancreatic Cancer
Funded at Oncotrap, INC. · NIH-10761053 · Data updated 2026-11-12
This study is testing a new treatment designed to target pancreatic cancer cells more effectively while sparing healthy cells, aiming to improve outcomes for patients battling this tough disease.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oncotrap, INC. NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $400,000 |
| NIH project number | 1R43CA281460-01A1 |
| Project ID | NIH-10761053 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who have limited treatment options.
✕Less likely to help
Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on developing a novel treatment for pancreatic ductal adenocarcinoma (PDAC), a type of cancer known for its poor prognosis. The approach involves creating an Aptamer-directed IgG1-Fc Drug Conjugate (AFDC) that specifically targets PDAC cells while minimizing effects on normal cells. By combining a unique aptamer that binds to cancer cells with a drug delivery system, the research aims to enhance the effectiveness of treatment and improve patient outcomes. The project will validate the ability of this new treatment to kill PDAC cells and optimize its formulation for clinical use.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment option for patients with pancreatic cancer, potentially improving survival rates.
How similar studies have gone: While antibody-drug conjugates have shown success in treating other cancers, this specific approach for pancreatic cancer is novel and has not been extensively tested.
Where this research is happening
-
Oncotrap, INC.
Chapel Hill, United States Active
Researchers
- Principal investigator: Gao, Xiang — Oncotrap, INC.
- Study coordinator: Gao, Xiang
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.